Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
NCT06331832
·
clinicaltrials.gov ↗
NO_LONGER_AVAILABLE
Status
INDUSTRY
Sponsor class
Conditions
Relapsed/Refractory Non-Hodgkin Lymphomas
Interventions
BIOLOGICAL:
IGM2323
Sponsor
IGM Biosciences, Inc.